Ireland's Amarin Q1 revenue rises 7% on higher international sales

Amarin

29/04/2026 12:22

Corrects product revenue to $43.3 mln, from $45.10 mln, in Key Details table

Overview

Ireland-based cardiovascular drug maker's Q1 revenue rose 7% yr/yr, led by higher international sales

Operating expenses fell 31%, reflecting cost cuts from global restructuring

Company generated positive cash flow and expects full-year positive cash flow

Outlook

Company expects to be cash flow positive for full year 2026

Amarin expects U.S. product volumes to remain stable throughout 2026

Company says European commercial partner plans to expand distribution across Europe over next several years

Result Drivers

INTERNATIONAL SALES - Higher international sales, especially in Europe through the Recordati partnership, contributed to revenue growth

U.S. PRESCRIPTION VOLUME - U.S. VASCEPA sales remained stable, benefiting from increased prescription volume after regaining exclusive status with a large national PBM

COST REDUCTIONS - Operating expenses fell sharply due to the June 2025 Global Restructuring and other cost optimization initiatives

Company press release: ID:nGNX696x1k

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$43.3 mln
Q1 Operating Expenses
$29.10 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Amarin Corporation PLC is $12.00, about 14% below its April 28 closing price of $13.96

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)